Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) and is active against many HIV type 1 PR variants resistant to earlier-generation PIs. Darunavir shows a high genetic barrier to resistance development, and virus strains with lower sensitivity to darunavir have a higher number of PI resistance-associated mutations than viruses resistant to other PIs. In this work, we have enzymologically and structurally characterized a number of highly mutated clinically derived PRs with high levels of phenotypic resistance to darunavir. With 18 to 21 amino acid residue changes, the PR variants studied in this work are the most highly mutated HIV PR species ever studied by means of enzyme kinetics and X-ray crystallography. The recombinant proteins showed major defects in substrate binding, while the substrate turnover was less affected. Remarkably, the overall catalytic efficiency of the recombinant PRs (5% that of the wild-type enzyme) is still sufficient to support polyprotein processing and particle maturation in the corresponding viruses. The X-ray structures of drug-resistant PRs complexed with darunavir suggest that the impaired inhibitor binding could be explained by change in the PR-inhibitor hydrogen bond pattern in the P2' binding pocket due to a substantial shift of the aminophenyl moiety of the inhibitor. Recombinant virus phenotypic characterization, enzyme kinetics, and X-ray structural analysis thus help to explain darunavir resistance development in HIV-positive patients.

Gilead Sciences and IOCB Research Center Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic v v i Flemingovo n 2 166 10 Prague 6 Czech Republic

000      

03760naa 2200553 a 4500

001      

bmc11016626

003      

CZ-PrNML

005      

20121113103708.0

008      

110628s2009 xxu e eng||

009      

AR

040    __

$a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Grantz Šašková, Klára $7 xx0110542

245    10

$a Molecular characterization of clinical isolates of human immunodeficiency virus resistant to the protease inhibitor darunavir / $c K. Grantz Šašková, M. Kožíšek, P. Řezáčová, J. Brynda, T. Yashina, R.M. Kagan, J. Konvalinka

314    __

$a Gilead Sciences and IOCB Research Center, Institute of Organic Chemistry and Biochemistry of the Academy of Sciences of the Czech Republic, v.v.i., Flemingovo n. 2, 166 10 Prague 6, Czech Republic.

520    9_

$a Darunavir is the most recently approved human immunodeficiency virus (HIV) protease (PR) inhibitor (PI) and is active against many HIV type 1 PR variants resistant to earlier-generation PIs. Darunavir shows a high genetic barrier to resistance development, and virus strains with lower sensitivity to darunavir have a higher number of PI resistance-associated mutations than viruses resistant to other PIs. In this work, we have enzymologically and structurally characterized a number of highly mutated clinically derived PRs with high levels of phenotypic resistance to darunavir. With 18 to 21 amino acid residue changes, the PR variants studied in this work are the most highly mutated HIV PR species ever studied by means of enzyme kinetics and X-ray crystallography. The recombinant proteins showed major defects in substrate binding, while the substrate turnover was less affected. Remarkably, the overall catalytic efficiency of the recombinant PRs (5% that of the wild-type enzyme) is still sufficient to support polyprotein processing and particle maturation in the corresponding viruses. The X-ray structures of drug-resistant PRs complexed with darunavir suggest that the impaired inhibitor binding could be explained by change in the PR-inhibitor hydrogen bond pattern in the P2' binding pocket due to a substantial shift of the aminophenyl moiety of the inhibitor. Recombinant virus phenotypic characterization, enzyme kinetics, and X-ray structural analysis thus help to explain darunavir resistance development in HIV-positive patients.

590    __

$a bohemika - dle Pubmed

650    _2

$a sekvence aminokyselin $7 D000595

650    _2

$a substituce aminokyselin $7 D019943

650    _2

$a vazebná místa $7 D001665

650    _2

$a krystalografie rentgenová $7 D018360

650    _2

$a mutační analýza DNA $7 D004252

650    _2

$a virová léková rezistence $7 D024882

650    _2

$a HIV infekce $x virologie $7 D015658

650    _2

$a HIV-proteasa $x genetika $x chemie $x metabolismus $7 D016333

650    _2

$a inhibitory HIV-proteasy $x farmakologie $7 D017320

650    _2

$a HIV-1 $x izolace a purifikace $x účinky léků $7 D015497

650    _2

$a lidé $7 D006801

650    _2

$a molekulární modely $7 D008958

650    _2

$a molekulární sekvence - údaje $7 D008969

650    _2

$a missense mutace $7 D020125

650    _2

$a polyproteiny $x metabolismus $7 D020815

650    _2

$a vazba proteinů $7 D011485

650    _2

$a terciární struktura proteinů $7 D017434

650    _2

$a sulfonamidy $x farmakologie $7 D013449

650    _2

$a genové produkty env - virus lidské imunodeficience $x metabolismus $7 D054299

650    _2

$a genové produkty gag - virus lidské imunodeficience $x metabolismus $7 D054301

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Kožíšek, Milan $7 xx0100179

700    1_

$a Řezáčová, Pavlína $7 xx0119409

700    1_

$a Brynda, Jiří $7 xx0100180

700    1_

$a Yashina, Tatyana

700    1_

$a Kagan, Ron M.

700    1_

$a Konvalinka, Jan, $d 1963- $7 mzk2004208597

773    0_

$t Journal of Virology $w MED00003048 $g Roč. 83, č. 17 (2009), s. 8810-8818

910    __

$a ABA008 $b x $y 2

990    __

$a 20110720115355 $b ABA008

991    __

$a 20121113103723 $b ABA008

999    __

$a ok $b bmc $g 864033 $s 726407

BAS    __

$a 3

BMC    __

$a 2009 $x MED00003048 $b 83 $c 17 $d 8810-8818 $m Journal of virology $n J Virol

LZP    __

$a 2011-3B09/BBjvme